For patients with high cholesterol, Praluent, also known by its generic name, alirocumab, is the new FDA approved drug that is effective at improving liver function to lower bad cholesterol (Goldschmidt). Unlike other available medication in the market, Praluent is a completely new class of drug that enhance the lives of many individuals and provides an alternative method for treating cholesterol that will appeal to patients who do not see results from their current medication or experience severe side effects.
Most current statins, like Lipitor, block the liver’s production of bad cholesterol. Praluent uses a different method in which antibodies target a protein called PCSK9 that generally maintains high levels of cholesterol in the liver …show more content…
The most significant difference between the two drugs is the number of dosage. As stated in the previous paragraph, Praluent requires patients to take 75 to 150 milligrams of injections every other week. On the other hand, Repatha requires injections to be given at around 140 milligrams every other week. Since Praluent and Repatha aims at the problem in similar and equally effective ways, future marketing strategies will be affected by these dosages. One major threat of Praluent’s competitor is that since Repatha is more potent, doctors and healthcare providers will be more likely to assign Repatha to a patient because of its convenience. This is a major problem because doctors are the primary target of the …show more content…
Visually, this requires a clean-cut and solid design that would allow patients to clearly notice the product without any distractions. Any advertisement released out into the market must be informational but easy to understand for the average person. Adverse effects must also be stated clearly so patients will understand the pros and cons of using Praluent as compared to its predecessors. Since Praluent is a completely new drug of its own kind, consumers needs to quickly gain trust in the product in order for it to succeed in the market. Since the mere idea of the drug peaks interest in all stakeholders of healthcare, creating a brand for the drug itself will not be a huge issue. Over time, Praluent will provide a sense of hope and opportunity for all patients with high cholesterol and healthcare providers in the pharmaceutical
Most current statins, like Lipitor, block the liver’s production of bad cholesterol. Praluent uses a different method in which antibodies target a protein called PCSK9 that generally maintains high levels of cholesterol in the liver …show more content…
The most significant difference between the two drugs is the number of dosage. As stated in the previous paragraph, Praluent requires patients to take 75 to 150 milligrams of injections every other week. On the other hand, Repatha requires injections to be given at around 140 milligrams every other week. Since Praluent and Repatha aims at the problem in similar and equally effective ways, future marketing strategies will be affected by these dosages. One major threat of Praluent’s competitor is that since Repatha is more potent, doctors and healthcare providers will be more likely to assign Repatha to a patient because of its convenience. This is a major problem because doctors are the primary target of the …show more content…
Visually, this requires a clean-cut and solid design that would allow patients to clearly notice the product without any distractions. Any advertisement released out into the market must be informational but easy to understand for the average person. Adverse effects must also be stated clearly so patients will understand the pros and cons of using Praluent as compared to its predecessors. Since Praluent is a completely new drug of its own kind, consumers needs to quickly gain trust in the product in order for it to succeed in the market. Since the mere idea of the drug peaks interest in all stakeholders of healthcare, creating a brand for the drug itself will not be a huge issue. Over time, Praluent will provide a sense of hope and opportunity for all patients with high cholesterol and healthcare providers in the pharmaceutical